Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

En studie av JNJ-80948543, en T-cellsomdirigerande antikropp, vid non-Hodgkin-lymfom (NHL) och kronisk lymfatisk leukemi (KLL)

25 september 2026 uppdaterad av: Janssen Research & Development, LLC

En fas 1, första i människa-studie av JNJ-80948543, en T-cellsomdirigerande antikropp, hos deltagare med NHL och CLL

The purpose of this study is to characterize safety and to determine the putative recommended Phase 2 dose(s) (RP2D[s]), optimal dosing schedule(s) and route(s) of administration of JNJ-80948543 in Part A (Dose Escalation) and to further characterize the safety of JNJ-80948543 at the putative RP2D(s) in Part B (Cohort Expansion).

Studieöversikt

Status

Aktiv, inte rekryterande

Intervention / Behandling

Studietyp

Interventionell

Inskrivning (Faktisk)

167

Fas

  • Fas 1

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studieorter

      • Macquarie University, Australien, 2109
        • Macquarie University Hospital
      • Melbourne, Australien, 3004
        • The Alfred Hospital
      • Nedlands, Australien, 6009
        • Linear Clinical Research Ltd
      • Randwick, Australien, 2031
        • Scientia Clinical Research
      • Copenhagen, Danmark, 2100
        • Rigshospitalet
      • Odense, Danmark, 5000
        • Odense University Hospital
      • Lille, Frankrike, 59037
        • CHRU de Lille Hopital Claude Huriez
      • Paris, Frankrike, 75005
        • Institut Curie
      • Strasbourg, Frankrike, 67033
        • Institut de Cancerologie Strasbourg Europe ICANS
      • Toulouse, Frankrike, 31059
        • Institut Universitaire du cancer de Toulouse-Oncopole
    • California
      • Duarte, California, Förenta staterna, 91010
        • City of Hope
    • New York
      • New York, New York, Förenta staterna, 10065
        • Memorial Sloan Kettering Cancer Center
      • New York, New York, Förenta staterna, 10029
        • Icahn School of Medicine at Mount Sinai
    • Tennessee
      • Nashville, Tennessee, Förenta staterna, 37203
        • Sarah Cannon Research Institute
    • Texas
      • Houston, Texas, Förenta staterna, 77030
        • The University of Texas MD Anderson Cancer Center
      • San Antonio, Texas, Förenta staterna, 78229
        • Texas Transplant Institute
    • Washington
      • Seattle, Washington, Förenta staterna, 98109
        • Seattle Cancer Care Alliance
      • Haifa, Israel, 34362
        • Carmel Medical Center
      • Jerusalem, Israel, 9112001
        • Hadassah Medical Center
      • Tel Aviv, Israel, 64239
        • Tel Aviv Sourasky Medical Center
      • Kashiwa, Japan, 277 8577
        • National Cancer Center Hospital East
      • Nagoya, Japan, 464 8681
        • Aichi Cancer Center
      • Tokyo, Japan, 135 8550
        • The Cancer Institute Hospital of JFCR
      • Chongqing, Kina, 400044
        • Chongqing University Cancer Hospital
      • Guangzhou, Kina, 510060
        • Sun Yat Sen University Cancer Center
      • Tianjin, Kina, 300060
        • Tianjin cancer hospital
      • Wuhan, Kina, 430030
        • Union Hospital Tongji Medical College of Huazhong University of Science and Technology
      • Gdansk, Polen, 80 214
        • Uniwersyteckie Centrum Kliniczne Osrodek Badan Klinicznych Wczesnych Faz
      • Skorzewo, Polen, 60-185
        • Aidport Sp z o o

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

18 år och äldre (Vuxen, Äldre vuxen)

Tar emot friska volontärer

Nej

Kön som är behöriga för studier

Allt

Beskrivning

Inclusion Criteria:

  • Histologic documentation of disease: B-cell non-Hodgkin lymphoma (NHL) or chronic lymphocytic leukemia (CLL) requiring therapy.

All participants must have relapsed or refractory disease with no other approved therapies available that would be more appropriate in the investigator's judgment.

B-cell NHL as defined per the 2016 world health organization (WHO) classification. In addition, the following disease-specific criteria outlined below must be met:

If diffuse large B-cell lymphoma (DLBCL) or other high-Grade B-cell lymphoma: Received, or not eligible for high-dose chemotherapy and autologous stem cell transplantation with curative intent or deemed not eligible or fit for an alternative 2nd line therapy. Participants may be eligible if relapsing after chimeric antigen receptors (CAR-T) cell treatment or while waiting for a CAR-T cell treatment.

If transformed lymphoma from low Grade B-cell malignancies: Received or not a candidate for an approved first-line regimen for DLBCL and received or not eligible for high-dose chemotherapy and autologous stem cell transplantation with curative intent.

If follicular lymphoma (FL) (all grades): Previously treated with a minimum of 2 prior lines of systemic therapy, with at least one prior line containing an anti-CD20 antibody.

If mantle cell lymphoma (MCL), marginal zone lymphoma (MZL) (including nodal, extranodal/MALT, and splenic MZL subtypes): Previously treated with at least 2 lines of systemic therapy. H.pylori-positive gastric MALT lymphoma must have failed prior H. pylori eradication therapy as one of their prior lines .

Waldenstrom macroglobulinemia (WM): Previously treated with at least 1 line of systemic therapy.

small lymphocytic lymphoma/chronic lymphocytic leukemia (CLL/SLL): Relapsed or refractory with at least 2 prior lines of therapy, including a Bruton tyrosine kinase inhibitor (BTK) inhibitor or a BCL2 inhibitor, if eligible. In addition for part B Participants must have measurable disease as defined by the appropriate disease response criteria

  • Eastern Cooperative Oncology Group (ECOG) performance status Grade of 0 or 1
  • Cardiac parameters within the following range: corrected QT interval (QTc intervals corrected using Fridericia's formula [QTcF]) less than or equal to (<=) 480 milliseconds based on the average of triplicate assessments performed no more than 5 (plus minus [+-] 3) minutes apart
  • A female participant of childbearing potential must have a negative highly sensitive serum pregnancy test (beta- human chorionic gonadotropin) at screening and must agree to further serum or urine pregnancy tests prior to the first dose, during the study and until 3 months after the last dose of study treatment
  • A female participant must agree not to be pregnant, breastfeeding, or planning to become pregnant while enrolled in this study or within 3 months after the last dose of study treatment

Exclusion Criteria:

  • Known active central nervous system (CNS) involvement; Lymphoma with CNS involvement may be allowed in pharmacokinetic/ pharmacodynamic (PK/PD) and expansion cohorts if approved by the study evaluation team (SET)
  • Prior solid-organ transplantation
  • Autoimmune or inflammatory disease requiring systemic steroids or other immunosuppressive agents (example, methotrexate or tacrolimus) within 1 year prior to first dose of study drug
  • Toxicity from prior anticancer therapy has not resolved to baseline levels or to Grade <= 1 (except alopecia, vitiligo, peripheral neuropathy, or endocrinopathies that are stable on hormone replacement, which may be Grade 2)
  • Clinically significant pulmonary compromise, particularly the need for supplemental oxygen use to maintain adequate oxygenation

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Behandling
  • Tilldelning: Icke-randomiserad
  • Interventionsmodell: Sekventiell tilldelning
  • Maskning: Ingen (Open Label)

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Experimentell: Part A: Dose Escalation

Participants will receive JNJ-80948543 either by subcutaneous (SC) or intravenous (IV) administration to determine the putative recommended Phase 2 dose (RP2D) dosing schedule(s) and route(s) of administration based on safety, pharmacokinetic, pharmacodynamic, and preliminary assessment of efficacy across several dose regimens.

JNJ-80948543 will be administered as SC or IV injection.

Experimentell: Part B: Cohort Expansion

Participants will receive JNJ-80948543 by SC or IV administration.

JNJ-80948543 will be administered as SC or IV injection.

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Number of Participants with Dose-limiting Toxicity (DLT)
Tidsram: Up to 4 Years 3 months

Number of participants with DLT will be reported. The DLTs are specific adverse events and are defined as any of the following: high grade non-hematologic toxicity, or hematologic toxicity.

Up to 4 Years 3 months
Number of Participants with Adverse Events (AEs)
Tidsram: Up to 4 Years 3 months

An AE is any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the intervention.

Up to 4 Years 3 months
Number of Participants with AE by Severity
Tidsram: Up to 4 Years 3 months

Severity will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE). Severity scale ranges from Grade 1 (Mild) to Grade 4 (Life-threatening). Grade 1= Mild, Grade 2= Moderate, Grade 3= Severe, Grade 4= Life-threatening and Grade 5= Death related to adverse event. Cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) will be graded as per American Society for Transplantation and Cellular Therapy (ASTCT).

Up to 4 Years 3 months

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Serum Concentration of JNJ-80948543
Tidsram: Up to 4 Years 3 months

Serum samples will be analyzed to determine concentrations of JNJ-80948543 using a validated, specific, and sensitive method.

Up to 4 Years 3 months
Number of Participants with Presence of Anti-Drug Antibodies of JNJ-80948543
Tidsram: Up to 4 Years 3 months

Number of participants with presence of anti-drug antibodies of JNJ-80948543 will be assessed.

Up to 4 Years 3 months
Overall Response Rate (ORR)
Tidsram: Up to 4 Years 3 months

ORR is defined as the percentage of participants who have a best response of partial response (PR) or better.

Up to 4 Years 3 months
Complete Response (CR) Rate
Tidsram: Up to 4 Years 3 months

CR rate is defined as the percentage of participants who achieve a best response of CR.

Up to 4 Years 3 months
Rate of VGPR or Better for Participants with Waldenstrom Macroglobulinemia (WM)
Tidsram: Up to 4 Years 3 months

The response criteria planned to be used for participants with WM includes a category of VGPR, which is clinically understood to be better than PR but not as good as CR. For participants with WM, this rate is defined as the proportion of participants who achieve a best response of VGPR or better.

Up to 4 Years 3 months
Time to Response (TTR)
Tidsram: Up to 4 Years 3 months

TTR is defined for participants who achieved PR or CR as the time from the first dose of study drug to first response of PR or CR.

Up to 4 Years 3 months
Duration of Response (DOR)
Tidsram: Up to 4 Years 3 months

DOR is defined for participants who achieved a response of PR or better as the time between the date of initial documentation of first response of PR or better to the date of first documented evidence of progressive disease or death.

Up to 4 Years 3 months

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Utredare

  • Studierektor: Janssen Research & Development, LLC Clinical Trial, Janssen Research & Development, LLC

Publikationer och användbara länkar

Den som ansvarar för att lägga in information om studien tillhandahåller frivilligt dessa publikationer. Dessa kan handla om allt som har med studien att göra.

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Faktisk)

18 augusti 2022

Primärt slutförande (Faktisk)

31 oktober 2025

Avslutad studie (Beräknad)

30 juli 2027

Studieregistreringsdatum

Först inskickad

15 juni 2022

Först inskickad som uppfyllde QC-kriterierna

15 juni 2022

Första postat (Faktisk)

21 juni 2022

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

28 september 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

25 september 2026

Senast verifierad

1 september 2026

Mer information

Termer relaterade till denna studie

Andra studie-ID-nummer

  • CR109174
  • 2022-000685-18 (EudraCT-nummer)
  • 80948543LYM1001 (Annan identifierare: Janssen Research & Development, LLC)
  • 2023-504187-42-00 (Registeridentifierare: EUCT number)
  • 2023 (U.S.S. NIH-anslag/kontrakt)

Plan för individuella deltagardata (IPD)

Planerar du att dela individuella deltagardata (IPD)?

JA

IPD-planbeskrivning

The data sharing policy of the Janssen Pharmaceutical Companies of Johnson & Johnson is available at www.janssen.com/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Ja

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera